Method Article
Here, the surgical induction of stable acquired lymphedema in the rabbit hindlimb is described. This experimental animal can be used to further investigate the effect of lymphedema treatment by microsurgical techniques.
Lymphedema is a common condition often associated with cancer and its treatment, which leads to damage to the lymphatic system, and current treatments are mostly palliative rather than curative. Its high incidence among oncologic patients indicates the need to study both normal lymphatic function and pathologic dysfunction. To reproduce chronic lymphedema, it is necessary to choose a suitable experimental animal. Attempts to establish animal models are limited by the regenerative capacity of the lymphatic system. Among the potential candidates, the rabbit hindlimb is easy to handle and extrapolate to the human clinical scenario, making it advantageous. In addition, the size of this species allows for better selection of lymphatic vessels for vascularized lymph node resection.
In this study, we present a procedure of vascular lymph node resection in the rabbit hindlimb for inducing secondary lymphedema. Anesthetized animals were subjected to circumferential measurement, patent blue V infiltration, and indocyanine green lymphography (ICG-L) using real-time near-infrared fluorescence, a technique that allows the identification of single popliteal nodes and lymphatic channels. Access to the identified structures is achieved by excising the popliteal node and ligating the medial and lateral afferent lymphatics. Special care must be taken to ensure that any lymphatic vessel that joins the femoral lymphatic system within the thigh without entering the popliteal node can be identified and ligated.
Postoperative evaluation was performed at 3, 6, and 12 months after induction using circumferential measurements of the hindlimb and ICG-L. As demonstrated during follow-up, the animals developed dermal backflow that was maintained until the 12th month, making this experimental animal useful for novel long-term evaluations in the management of lymphedema. In conclusion, the approach described here is feasible and reproducible. Additionally, during the time window presented, it can be representative of human lymphedema, thus providing a useful research tool.
Lymphedema is a chronic condition that deserves special attention, owing to its worldwide incidence, lack of curative and standardized treatment, and serious impact on patients' quality of life1,2.
In developed countries, lymphedema is mainly acquired and is secondary to breast cancer, owing to the high prevalence of this malignancy; the cumulative incidence of breast cancer-related lymphedema 10 years after surgery can reach up to 41.1%3. However, diseases such as melanoma, gynecological cancers, genitourinary tumors, and head and neck neoplasms are also associated with a high incidence of this disease4. Regional lymph node resection, as part of the necessary oncological treatment to increase survival rates, leads to the disruption of functional lymphatic drainage. In some cases, this results in compensatory mechanisms that prevent or delay the onset of lymphedema5. However, when chemotherapy and radiotherapy are administered, these mechanisms are not able to compensate for the change, and lymphedema resultantly occurs. This has a negative impact on patients' quality of life, affecting their functional, social, and psychological well-being6,7.
The need for an effective cure for lymphedema requires understanding of the physiopathology of the lymphatic system, as well as a deep insight into the complex cellular mechanisms and their responses in both normal and dysfunctional lymphatic systems8,9,10. Such insights can be obtained initially from experimental animal models that can reproduce chronic human diseases11.
Many attempts have been made to replicate lymphedema in experimental animal models; however, most of them have been hindered by some limitations, including the inability to reproduce chronic lymphatic insufficiency in a stable animal model, the costs of the study, and most importantly, the great regenerative capacity of the lymphatic system, which enables it to restore circulation12,13.
This study presents the experimental approach for surgically inducing stable acquired lymphedema using the rabbit hindlimb. Based on literature review, this animal can be considered optimal for the development of lymphedema because of the consistent anatomy of its hindlimb lymphatic system, which includes a single popliteal node that drains the hindlimb and reaches the main femoral lymphatic system in the leg14,15.
The specific anatomy of the rabbit's hindlimb allows for the reproduction of the surgical procedures performed in humans to induce secondary lymphedema. Therefore, this procedure can be used for microsurgical training and preclinical research to extrapolate the results to human medicine.
All procedures were approved by the ethical committee of the Jesús Usón Minimally Invasive Surgery Center and the welfare guidelines of the regional government, which are based on European legislation.
1. Presurgical and surgical preparation
2. Popliteal vascular lymph node resection surgery (Figure 1)
3. Postoperative evaluation
Nine rabbits underwent lymphedema induction in this study, however, three rabbits died during the immediate postoperative period and could not be evaluated. Study data were obtained at 3, 6, and 12 months postoperatively by three independent researchers. Circumferential hindlimb measurements and ICG-L were performed under general anesthesia to assess the lymphatic system function and dermal backflow.
The data obtained by ICG-L at 3 months postoperatively showed dermal backflow and the absence of PLNs in the left hindlimbs of the rabbits, compatible with the disruption of normal lymphatic system function. ICG-L results at 6 and 12 months postoperatively showed dermal backflow and dilated lymphatic channels distal to the popliteal fossa during surgical exploration (Figure 8).
No evidence of clinical lymphedema was found upon examination or circumferential hindlimb measurements. The increase in the volume of the left hindlimb was not significant (p < 0.05) compared to that of the right hindlimb (control) (Figure 9). All results obtained from the left hindlimb were compared with those obtained from the right hindlimb of the same animal, which was used as the negative control.
In the described surgical procedure, after PLN resection and ICG application, no compromised blood flow was observed in the hindlimb, no alteration in vital parameters was reported during anesthesia, and no pain or lameness was described. All parameters were assessed according to the guidelines for quantifying pain, stress, and distress in laboratory animals16,17,18,19.
Figure 1: Experimental surgical procedure for the induction of lymphedema. Detailed protocol for the creation of a vascular lymph node resection in the left hindlimb of the rabbit for the induction of secondary lymphedema. Abbreviations: LN = lymph node; VLN = vascular lymph node. Please click here to view a larger version of this figure.
Figure 2: Preoperative markings of rabbit hindlimbs. Skin marks on the left hindlimb show the measurement points every 2 cm (blue arrow) and a healthy lymphatic system drawn with a surgical marker (red arrow) observed by ICG-L. Scale bar = 2 cm. Abbreviation: ICG-L = indocyanine green lymphography. Please click here to view a larger version of this figure.
Figure 3: Preoperative ICG-L showing the popliteal lymph node and afferent lymphatic vessels from the rabbit hindlimb. Abbreviation: ICG-L = indocyanine green lymphography. Please click here to view a larger version of this figure.
Figure 4: Lymphatic and vascular structures. Popliteal lymph node (asterisk) with an afferent lymphatic vessel (arrow). Please click here to view a larger version of this figure.
Figure 5: Principal lymph vessels. (A) Identification of the two main lymphatic vessels running parallel to the saphenous vein distal to the PLN by surgical microscopy without ICG. (B) Identification of the two main lymphatic vessels running parallel to the saphenous vein distal to the PLN with ICG. Scale bar = 1 cm. Abbreviations: PLN = popliteal lymph node; ICG = indocyanine green. Please click here to view a larger version of this figure.
Figure 6: PLN pedicle. (A) Identification of the PLN pedicle by surgical microscopy without ICG. (B) Identification of the PLN pedicle with ICG. Scale bar = 1 cm. Abbreviations: PLN = popliteal lymph node; ICG = indocyanine green. Please click here to view a larger version of this figure.
Figure 7: Two groups of afferent lymphatic vessels that do not enter the PLN but directly join the femoral lymphatic system within the thigh. Popliteal lymph node (asterisk) with an afferent lymphatic vessel transected (arrows). Scale bar = 1 cm. Please click here to view a larger version of this figure.
Figure 8: Preoperative and postoperative ICG-L. (A) Preoperative ICG-L showing healthy linear lymphatics in the hindlimb.(B) Postoperative ICG-L showing dermal backflow pattern in the rabbit lymphedematous hindlimb. Abbreviation: ICG-L = indocyanine green lymphography. Please click here to view a larger version of this figure.
Figure 9: Circumferential hindlimb measurements. The red column chart corresponds to the right hindlimb measurements, while the green column chart corresponds to the left hindlimb measurements. The increase in volume of the left hindlimb was not significant (p < 0.05) compared to the control right hindlimb. Please click here to view a larger version of this figure.
Resection of the PLN in an experimental animal is a relatively new procedure that can induce secondary lymphedema in the limbs for assessment and study. After lymph node resection, there is a period of alteration of lymphatic system functionality, lymph accumulation, and histological changes of lymphatic vessels that appear dilated. When this lymph accumulation reaches adequate levels, the characteristic dermal backflow of lymphedema, similar to that observed in humans, can be observed using objective techniques such as ICG-L. The development of this technique may create a cost-effective preclinical research animal, which may help prevent and treat this pathophysiological process.
Intraoperatively, patent blue V application can identify the presence or absence of flow through the lymphatic vessels of the hindlimbs5. The disadvantage of this technique is that the lymphatic vessels can only be observed intraoperatively. Therefore, a real-time near-infrared fluorescence camera technology is used, which is an excellent method that allows surgeons to identify, map, and quantify lymph flow in the lymphatic channels of the application site without the need for surgery. Nowadays, this technology is considered the gold standard for lymphedema diagnosis.
In this study, all lymphatic vessels that were observed and identified by ICG and patent blue V were patent. After resection of the PLN, the left hindlimbs presented dermal backflow at 3, 6, and 12 months after induction and linear functional lymphatic vessels were not present. This predicted good lymph stasis in the left hindlimb during the total study period. These results suggest the successful creation of secondary lymphedema in an experimental animal over a longer period than in previous studies5. However, this technique has its limitations. To obtain reliable results, all vascular and lymphatic structures of the PLN must be ligated and removed, as well as the surrounding fatty tissue, to avoid possible lymphangiogenesis. In addition, because of the physiology of the lymphatic system in rabbits15,20, no evidence of clinical lymphedema was demonstrated upon examination or circumferential hindlimb measurements, in contrast to other studies using the same experimental animal5.
A real-time near-infrared fluorescence camera was used during follow-up. This technology, with its high sensitivity, represents a valuable technique for real-time mapping of lymphatic vessels and lymph nodes, as verified here. Patent blue V is more widely used but is less specific and limited by the fact that lymphatic vessels can only be observed under intraoperative microscopic vision, whereas ICG allows the detection of these same vessels and lymph nodes without the need for any surgical intervention.
The present study demonstrated that the rabbit is a reliable, reproducible, and affordable experimental animal for the surgical induction of lymphedema. The consistent lymphatic system anatomy of the hindlimbs with a unique PLN permits the induction of long-term and stable lymphedema. This makes the rabbit a useful animal for both lymphedema experimentation and research.
The authors have no conflicts of interest to disclose.
This research project was performed at the Jesús Usón Minimally Invasive Surgery Center (CCMIJU), which is part of the ICTS Nanbiosis. The study was performed with the assistance of the following Nanbiosis units: U21, experimental operating room, and U22, animal housing. This work was supported by Hospital de la Santa Creu i Sant Pau. This work has been partially funded by the Junta de Extremadura, the European Regional Development Fund (Grant Number GR21201). The funder played a role in the study design, data collection, analysis, decision to publish, and manuscript preparation. Special thanks are extended to María Pérez for preparing the figures and to the Microsurgery Department of JUMISC for providing constant encouragement.
Name | Company | Catalog Number | Comments |
Bleu Patente V sodique (Guerbet) | Guerbet. Villepinte, France | 2.5 g/100 mL | |
Buprenorphine (Bupaq) | Richter Pharma. Wels, Austria | 0820645AA | 3 mg/10 mL |
Fluobeam | Fluoptics. Grenoble, France | Fluorescence imaging | |
IBM SPSS software | IBM | version 21.0 | |
Indocyanine green (Verdye, Diagnostic Green GmbH) | Diagnostic Green GmbH. Aschheim-Dornach, Germany | 5 mg/mL | |
Ketorolaco (Normon) | Normon, S.A. Madrid, Spain | T01H | 30 mg/mL |
Microsoft Excel | Microsoft | version 16.66.1 | |
Midazolam (Normon) | Normon, S.A. Madrid, Spain | T35M | 15 mg/3 mL |
Pentero 800 microscope, fluorescence module | Carl Zeiss Meditec AG. Goeschwitzer Strasse 51-52. Jena, Germany | 302581-9245-000 | |
Potassium chloride (Braun) | B.Braun. Barcelona, Spain | 19262010 | 20 mmol/10 mL |
Propofol (Propomitor, Orion Pharma) | Orion Pharma. Spoo, Finland | 20R039B | 200 mg/20 mL |
RÜSCH endotracheal tubes | Teleflex Medical IDA Business and Technology Park. Athione, Ireland. | 12CE 12 | Size Tube 4.0 I.D. mm |
Sevoflurano (SevoFlo, Zoetis) | Zoetis Belgium. Luvain-la-Neuve, Belgium | 6093559 | 1000 mg/g (250 mL) |
Tramadol (Normon) | Normon, S.A. Madrid, Spain | T08U | 100 mg/2 mL |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved